Detail review on pharmacokinetic parameters, efficacy and safety of Ertugliflozin

Type 2 diabetes mellitus is a complex and chronic metabolic condition affecting 463 million people over all the word and is projected to affect 700 million by 2045. Type 2 diabetes mellitus is a prevalent, progressive disease with a need for innovative therapeutic agents to continue to advance disease management. SGLT2 inhibitors are newer, potent, anti-diabetic agents, which are inhibiting glucose reabsorption by Sodium glucose co-transporter inhibitors and increasing urinary glucose excretion from kidney. Treatment in type-2 diabetic mellitus patients with SGLT 2 inhibitors like Ertugliflozin used as a mono therapy or combination therapy with other oral anti-diabetic agents. In the summary data concerning about its chemistry, Pharmacokinetic, efficacy and safety profile of ertugliflozin as alone without addition to other oral hypoglycaemic agents of type-2 diabetes mellitus. Base on clinical trial, ertugliflozin effectively reduce glycolated haemoglobin (HbA1c), body weight and blood pressure on the type-2 diabetic patients.